Mark Sheptoff Financial Planning, LLC Gilead Sciences, Inc. Transaction History

Mark Sheptoff Financial Planning, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 10, 2019	SELL	$62.53 - $70.05 $13,569 - $15,200	-217 Closed	0 $0
Q4 2018 Feb 11, 2019	BUY	$60.54 - $79.0 $121 - $158	2 Added 0.93%	217 $14,000
Q3 2018 Nov 13, 2018	BUY	$71.28 - $78.92 $71 - $78	1 Added 0.47%	215 $17,000
Q2 2018 Aug 09, 2018	SELL	$64.88 - $75.68 $562,704 - $656,372	-8,673 Reduced 97.59%	214 $15,000
Q1 2018 May 08, 2018	SELL	$72.84 - $88.8 $82,382 - $100,432	-1,131 Reduced 11.29%	8,887 $670,000
Q4 2017 Feb 09, 2018	SELL	$71.15 - $83.52 $272,077 - $319,380	-3,824 Reduced 27.63%	10,018 $718,000
Q3 2017 Nov 09, 2017	BUY	$72.11 - $85.47 $998,146 - $1.18 Million	13,842	13,842 $1.12 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Mark Sheptoff Financial Planning, LLC, based on Form 13F filings with the SEC.

Stay updated on Mark Sheptoff Financial Planning, LLC with notifications on news.